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Abstract
There are over 1 million hospitalizations for heart failure (HF) annually in the United States alone,
and a similar number has been reported in Europe. Recent clinical trials investigating novel
therapies in patients with hospitalized HF (HHF) have been negative, and the post-discharge event
rate remains unacceptably high. The lack of success with HHF trials stem from problems with
understanding the study drug, matching the drug to the appropriate HF subgroup, and study
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execution. Related to the concept of study execution is the importance of including appropriate
study sites in HHF trials. Often overlooked issues include consideration of the geographic region
and the number of patients enrolled at each study center. Marked differences in baseline patient
co-morbidities, serum biomarkers, treatment utilization and outcomes have been demonstrated
across geographic regions. Furthermore, patients from sites with low recruitment may have worse
outcomes compared to sites with higher enrollment patterns. Consequently, sites with poor trial
enrollment may influence key patient end points and likely do not justify the costs of site training
and maintenance. Accordingly, there is an unmet need to develop strategies to identify the right
study sites that have acceptable patient quantity and quality. Potential approaches include, but are
not limited to, establishing a pre-trial registry, developing site performance metrics, identifying a
local regionally involved leader and bolstering recruitment incentives. This manuscript
summarizes the roundtable discussion hosted by the Food and Drug Administration between
members of academia, the National Institutes of Health, industry partners, contract research
organizations and academic research organizations on the importance of selecting optimal sites for
successful trials in HHF.
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Introduction: an open forum
Recent clinical trials investigating therapies for patients hospitalized for heart failure (HF)
have failed to show benefit with respect to key end points [1–3]. Possible explanations
include an inadequate understanding of the study drug properties, failure to match the study
drug with the correct patient population and poor study execution. However, the main reason
for this continued lack of success may be related to the majority of studies focusing on
short-term therapies to improve signs and symptoms during hospitalization that are already
known to improve with standard therapy [4]. Few studies have concentrated on the
unacceptably high post-discharge event rate, which has been shown to occur despite the use
of current evidence based therapies [1, 5]. Accordingly, there is an unmet need to develop
new therapies to improve post-discharge outcomes in this patient population. This is even
more important in patients with hospitalized heart failure (HHF) with preserved ejection
fraction for whom no evidence-based therapies exist [6].
Multiple reasons for the repeated failure of clinical trials have been addressed in prior
meetings [7–10]. However, one topic of increasing importance with global clinical trials that
has yet to be addressed in an open forum is the importance and method of quality site
selection in trials of HHF. This manuscript summarizes the roundtable discussion between
members of academia, the National Institutes of Health (NIH), various industry partners,
contract research organizations (CRO) and academic research organizations (ARO) on the
importance of selecting optimal sites for a successful trial. This meeting was hosted by the
Food and Drug Administration (FDA) on January 12, 2012 in Silver Spring, Maryland (see
Appendix 1 and 2). For clarity, a summative impression is provided for each individual
participant.
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Trials in patients hospitalized for heart failure to date: an overview
Mihai Gheorghiade—There are over one million hospitalizations for HF in the United
States alone [11], and a similar number is seen in Europe. Despite available therapies,
mortality and rehospitalization rates can be as high as 15 and 30 %, respectively, within 60–
90 days post-discharge [12]. The majority of these patients are elderly (median age 75 years)
and have a history of cardiovascular (coronary artery disease [CAD] ~60 %, hypertension
~70 %, atrial fibrillation ~40 %) and non-cardiovascular comorbidities (diabetes ~40 %,
severe renal impairment ~30 % and chronic obstructive pulmonary disease ~25 %) [13–15].
To date, the majority of trials conducted in HHF have focused on improving early signs and
symptoms with short-term treatments. These trials have targeted therapies for patients at
time of initial presentation and during the hospitalization and are thus classified as Stage A
and Stage B trials, respectively [8, 10, 16]. Unfortunately, with the exception of the
EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with
Tolvaptan) and the ongoing ASTRONAUT (Aliskiren Trial on Acute Heart Failure
Outcomes) trials [1, 17], there have been few Stage C trials where therapies are initiated
before or soon after discharge and effects on post-discharge event rates are evaluated. while
standard in-hospital therapies may improve symptoms in the majority of patients, there is an
apparent dissociation between these improvements and post-discharge outcomes [10]. We
now realize that the major goal in HHF is to improve the unacceptably high post-discharge
event rate rather than clinical signs and symptoms [18].
Additional problems with HHF trials stem from the aforementioned problems with
understanding the study drug [19], matching the drug to the correct patient [4, 10], and study
execution. Overall, the properties of pharmacologic therapies in HHF patients are poorly
characterized. Even widely available guideline recommended agents for chronic HF have
not been specifically studied in the setting of HHF. Furthermore, many new HHF trials are
limited by investigating novel molecules with poorly described properties and mechanisms
of action.
The heterogeneity of clinical profiles, etiologies, substrates and precipitants in HHF patients
necessitates new trials to only include the subset of patients most appropriate for a given
therapy. By analogy, progress in the treatment of acute coronary syndromes (ACS) has been
aided by the recognition of discrete subpopulations (ST-segment elevation myocardial
infarction vs. non-ST-segment elevation myocardial infarction vs. unstable angina) and the
realization that effective therapies for one subgroup (such as thrombolytics for ST-segment
elevation myocardial infarction) are not helpful for another (such as unstable angina) [8].
However, even when a study drug is well characterized and matched with the appropriate
HHF subpopulation, proper study execution remains a significant obstacle. Recently, even
the TIMI (Thrombolysis in Myocardial Infarction) Study Group, among the most
experienced AROs in cardiology with an impressive track record, has encountered problems
in trial execution. The Rivaroxaban in ACS ATLAS-TIMI 51 program found that
rivaroxaban safely reduced the primary efficacy end point, but the drug was subsequently
not approved by the FDA due to missing study data [20]. These difficulties encountered by
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an experienced and well-established ARO highlight how challenging sound study execution
can be.
Related to study execution is the importance of including appropriate study sites in HHF
trials. The EVEREST trial illustrated that with site selection, it is necessary to consider both
geographic region and the number of patients enrolled at a center [1]. Preliminary
unpublished data from EVEREST demonstrated marked differences in baseline patient co-
morbidities (i.e. CAD, hyperlipidemia, diabetes and chronic kidney disease), serum B-type
natriuretic peptide (BNP) and QRS duration across geographic regions. Regional differences
also existed in regard to HF treatment utilization and rates of death and HF hospitalization.
Furthermore, patients from sites with low recruitment (10 or fewer during the trial duration)
had poorer outcomes compared to sites with higher enrollment patterns. Overall, EVEREST
randomized 4133 patients from 359 sites, corresponding to an enrollment rate of only 0.41
patients/site/month. This enrollment rate is consistent with other large HF trials such as
ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Subjects with
Decompensated Heart Failure) and EMPHASIS-HF (Eplerenone in Mild Patients
Hospitalization And Survival Study in Heart Failure) [2, 21].
As depicted in EVEREST, sites with poor trial enrollment may influence key patient end
points making evaluation of the study drug implicitly difficult. From the administrative
standpoint, each individual site and investigator may have proportionally less training,
infrastructure and investment. Low volume recruitment likely does not justify the costs of
site training and maintenance. Accordingly, there is an unmet need to develop strategies to
identify quality study centers that have acceptable patient quantity and quality. One
proposed solution involves the use of a pre-trial registry and the development of site
performance metrics. Such a system has several advantages including characterization of the
target study population (i.e. number of patients, demographic variables, HF etiologies), the
clinical course of disease (i.e. length of hospital stay, post-discharge patient disposition) and
the post-discharge event rate at each potential study site. If a center is determined to be
under-performing or an outlier in one or more of these areas, corrective efforts may be
employed or the center may be excluded from the subsequent trial. Furthermore, a pre-trial
registry would help ensure adequate trial enrollment to achieve the necessary study power
and also provides centers the opportunity for a “dry-run” as they become familiar with data
collection, protocol and terminology.
Other fields in medicine such as oncology have had more success with trial recruitment and
patient participation. The fundamental difference between oncology and cardiology/ HF in
terms of clinical trial participation revolves around perception and messaging (Table 1).
Despite similar rates of 1-year mortality in many cases, cancer patients are aware of their
limited therapeutic options, and oncologists reinforce that clinical trials may offer them the
only possible solution; hence, trial participation is high. Similarly, patients experiencing
acute myocardial infarctions (AMI) are recognized to have poor outcomes and thus are
actively and promptly enrolled in clinical trials. In contrast, HHF patients are rarely made
aware of their poor prognosis, and since symptomatic relief is achieved fairly readily with
use of diuretic strategies, patients and physicians do not perceive clinical worsening and
necessity for clinical trial enrollment. In addition, clear subgroups have been established in
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cancer patient cohorts (genetic-based) and AMI patients (ST-segment elevation vs. non-ST-
segment elevation). Unfortunately, in HHF, the lack of established subgroups make specific
trial enrollment difficult. Cancer investigators have utilized a series of disease-oriented
networks to help identify and select appropriate patients for individual trials.
Geographical disparities in acute heart failure trials
Marco Metra—Historically, trials in cardiology prior to 1990 had significantly fewer sites
and more success with patient recruitment per site. There have been a number of important
changes in this area including rapid globalization of HHF trials in recent years. Improved
background therapy for patients with chronic HF has reduced overall event rates and forced
detection of smaller effect sizes in trial settings. This change, in combination with the need
for unquestionable safety data and the goal to broaden the potential market, has contributed
to dramatic increases in the size and cost of clinical trials (Fig. 1). Concurrently, we have
seen a reduction in overall enrollment rates in the US and Western Europe [22] and rapid
rise in globalization of HHF trials. Indeed, this pattern of trial enrollment with marked
geographical variation has been observed in a number of disease conditions. However,
increased geographic differences in patient baseline characteristics and outcomes are now
recognized, and the need to further increase the number of patients and the duration of
randomized controlled trials creates a positive feedback loop toward further heterogeneity of
a study population (Fig. 2). Globalization of HHF trials and increased disparities between
different geographical areas, associated with the intrinsic heterogeneity of HHF and the lack
of well-characterized knowledge of HHF sites, have increased the intrinsic variability of the
study population, thus making the detection of a meaningful drug effect less likely.
Characteristics of an “Ideal Site”
Gadi Cotter—In North America and Western Europe, enrollment in clinical HHF studies
has decreased in the last decade. Typical sites now enroll 1–2 patients per year out of
hundreds of HF admissions. Low enrollment suggests increased selectivity such that the
study patients may not represent the real-world HF population, especially if enrollment is
biased by socioeconomic status and adherence. Increasing variability in the study population
may translate into inaccurate estimates of the treatment effect in the target population, and
greater dilution of the drug effect. Lower enrolling centers may have less infrastructure and
fail to properly select patients and favor the inclusion of patients less likely to benefit from
the studied therapy. These centers may be less familiar or adherent to strict protocols, have
less structured recourses to conduct the study, and may have too many competing studies or
higher dropout rates and poor follow-up. Hence, accurate interpretation of treatment effect
estimates across all enrolling sites is complex. Does a trial with 100 centers enrolling 4,000
patients over 2 years produce different findings from a trial with 1,000 centers enrolling the
same number of patients over the same time? There is a tenuous balance between enrolling a
sufficient number of patients and selecting the “right” patient (quality vs. quantity).
Furthermore, there is increasing recognition of the impact of regional differences on
outcomes in HF trials [23]. As low enrollment and regional differences interact with
unpredictable ways, there is concern for further bias of trial results.
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Low enrolling sites may result in high cost, reduced innovation and poor quality. The “fixed
cost” of opening a site ($30,000–$50,000) and keeping a site open ($3000– $5000/month)
make studies enrolling thousands of sites prohibitively expensive. Many sites with few or no
patients will not justify the cost of training and site maintenance. Sites may not have
sufficient resources (study physicians, nurse/site coordinators), expertise in the disease area,
prior trial experience or a patient population meeting study selection criteria to allow for
adequate recruitment. Since reimbursement and recognition for increased recruiting is poor,
sites lack motivation and become overworked without adequate compensation. Furthermore,
too many sites create costly logistical issues. These high costs limit the number of new
interventions that will be examined in phase III clinical studies, causing early abandonment
of potentially effective interventions.
Clearly, there is no one ideal site for all studies. For instance, studies enrolling patients with
acute pulmonary edema may do less well in trials testing an agent targeting refractory,
inotrope-dependent HF. Do there need to be fundamentally different approaches to
identifying centers and investigators for participating in HHF trials as compared to chronic
HF trials? As a general rule, site enrollment needs to be tailored depending on the specific
intervention under investigation.
In order to successfully conduct studies, site personnel should be interested in study
involvement at multiple levels, including the program director (cardiology, heart failure and
emergency department), sub-investigators (junior faculty and fellows), and perhaps most
importantly, the study coordinator. To maximize interest, studies should exhibit scientific
merit, be well designed and, most importantly, be simple to execute.
Experienced, motivated and well-compensated study personnel are key to successful
enrollment. First, site personnel should be experienced in conducting such studies,
especially those in HHF. Second, personal relationships between local staff and operational
leadership are crucial to maintain motivation. Third, local leadership through regional
leaders is critical. Selecting the wrong country PI can lead to poor motivation of his/her
colleagues. Finally, compensation of investigators, coordinators and co-investigators is
essential as there needs to be strong motivation for sites to enroll patients. However, the
specific methods of such techniques are unclear in a climate with low reimbursement, a lack
of site recognition of the merit of conducting trials (e.g. increasing workload without
compensation or authorship on trial manuscripts) and concerns that monetary incentives for
investigators may encourage protocol violations.
Food and drug administration
Norman L. Stockbridge—Heart failure trialists often compare the public health burden
of their disease to the one treated by oncologists, but the former fail to learn the latter’s
lesson. A high proportion of practicing oncologists participate in clinical research on a
continuing basis [24], and they foster that culture among their patients.
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Chris Giordano—Current practices of site enrollment are strongly driven by timelines and
target overall enrollment rates, missing key steps along the site enrollment process. New
models should occur in three distinct stages. The first stage is the site and patient selection
stage. Large populations of patients must be analyzed to find patients’ meeting enrollment
criteria and to determine the sites with access to these patients. For efficiency and quality,
these should not be created in a vacuum, but rather compiled by a cohort of organizations
including ARO networks, the National Lead network (part of the ARO contribution) and
CROs. Well-performing sites that have previously investigated the study agent or recruited
the study population of interest should also be specially invited to participate. The second
stage is evaluating feasibility—the scientific/academic leadership should provide a draft
protocol and detailed questionnaire to help determine site and patient criteria. Logistical
elements such as the anticipated number of sites, length of recruitment and potential
challenges should be identified. Site participation in this developmental stage can help gauge
site interest/engagement. This participation further allows us to inspire a sense of
“ownership” of the trial. Sites that demonstrate that they can build the cross-specialization/
department network and create “ownership” of the trial within their institution will properly
recruit into the trial and may yield the required patients since these same two factors drive
subject volume and appropriateness. The final stage and perhaps the most important is the
verification phase. Although site selection visits can be costly and time-consuming, they
may prove invaluable to avoid downstream unanticipated problems/issues. During this final
stage, these site selection visits can be targeted at fewer, more qualified sites that have been
identified in previous stages, thus potentially reducing the overall costs of site monitoring.
Although it has been proposed that utilization of a registry instrument may aid in the
recruitment of quality sites and patients, this approach presents some concerns. Some quality
sites interested in a Phase II/III study may not be interested in investing time and burden in a
registry. Furthermore, sites willing to participate in a pre-trial-specific registry may not be
predisposed toward a nationwide HHF registry in which their performance (exams and
treatments) may be measured in a non-anonymous manner. The registry only provides a
snapshot of a site profile/ capacity/performance which is likely to be dependent on site
personnel. Unfortunately, emergency department (ED) site personnel experience high
turnover.
Academic research organizations
W. Frank Peacock—While an ARO may exemplify process and infrastructure unique
from that of their CRO counterpart, ultimately, they share nearly identical needs.
Specifically, both types of research organizations require reasonable clinical and economic
efficiency from the institutions they partner with. Without this efficiency, poor protocol
compliance and high rates of adverse events from non-standard clinical care increase the
study population and costs needed to determine the experimental intervention’s effect.
Ideally, a smaller number of efficient centers would have important impacts on study costs,
enrollment goals and potentially clinical outcomes.
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The historical strategy of increasing the number of sites to reach enrollment targets is
doomed to failure without considering financial and clinical efficiency. Very low enrollment
is usually the consequence of a lack of infrastructure, not lack of patients. Knowledge of the
ED census can approximate a site’s potential acute HF population. In 2012, there will be an
estimated 130 million US emergency department visits. Of these, 1 % (1.3 million) will
suffer acute HF, and 1.04 million will be hospitalized [25]. Since acute HF is for the most
part uniformly distributed across the North American continent, we can predict a site’s
potential acute HF population. To recruit these potential participants, infrastructure needs to
be where the patients are, when the patients are there. Most patients present to the ED at
non-business hours. A 9a–5p research nurse in the department of heart failure is in the
wrong department and available at the wrong time to enroll many acute heart failure
patients.
Further, although most HF research is performed by HF cardiologists, most HF patients are
not immediately hospitalized under the care of a HF cardiologist. After an ED evaluation,
most HF patients are admitted to internal medicine, family practice or a hospitalist service.
HF specialists may not care for the patient until after trial enrollment eligibility has expired.
The ED is the one common location of the dispersed population of the one million US acute
HF patients. Importantly, although the presence and location of acute HF patients are
predictable, it too is challenging. In a 75,000 annual visit ED, there will be approximately
750 annual acute HF presentations. This is about 2 patients per day, both of whom may
arrive after 11 pm. Ultimately, larger centers (i.e. more potential candidates for study entry)
with more hours of ED research coverage per day (i.e. greater probability of capture) will
have greater enrollment success than centers that do not have these characteristics. Finally,
potential site selection in future research projects requires objective prospective evaluation
of their probability for success. Although not validated, metrics that may be useful appear in
Table 2.
Faiez Zannad: Fight-HF Alliance—Certain inherent challenges exist with HHF trial
execution. The definition of HHF is commonly based on gradual or rapid onset of HF signs
and symptoms requiring urgent therapy. The patient population is highly heterogeneous, and
the definition is dependent on clinical judgment, open to selection bias and does not
categorize the multiple phenotypes. The severity of symptoms that mandates patient
admission is very subjective and may vary widely across various healthcare systems. There
are no robust diagnostic ascertainment criteria such as electrocardiogram and enzymes for
myocardial infarction. The use of BNP as an inclusion criterion is not standard practice and
has limitations. Patients proceed through a continuum of stages from the ED to post-
discharge, and the place to screen for and optimally enroll patients with HHF may vary from
EDs, intensive care units (ICU), general ward, internal medicine, cardiology departments or
HF units, according to the stage of the disease that is targeted in specific trials. The TIMI
group experience has capitalized on the structuring of healthcare systems worldwide for the
specific coordinated and integrated management of ACS worldwide that led to ICUs in the
seventies. A similar structuring effort for the management of HHF, a condition that has
grown to become twice as frequent and more severe than ACS, is an unmet need. Only such
structuring may ultimately lead to the emergence of HHF—minded and trained dedicated
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physicians with experience in clinical trials and acute management of HF. Large regional
variation exists and the individual investigators magnify this heterogeneity. The treatment
and management of patients with HHF is largely multi-disciplinary, and thus no particular
treating physician takes ownership. Follow-up after hospitalization remains particularly
challenging and is also influenced by regional differences in healthcare systems.
Fight-HF Alliance represents a global ARO aimed at optimizing execution of HHF trials.
The principles underlying this organization include establishing a better understanding of the
disease and its heterogeneity across clinical practices, specialties, regions and healthcare
systems. It tries to provide a durable and extensive global registry database available for
queries to allow for trial design optimization, identification of target populations, pre-trial
market research and health economics/analysis. This provides a huge opportunity for
training and investigator consortium building. Furthermore, Fight-HF provides academic
expertise in designing clinical trials and maximizing knowledge production. It aims at
identifying, creating, training and certifying networks of multidisciplinary investigators/
teams profiled to the specific needs of HHF trials, led by active lead country investigators.
Dirk J. van Veldhuisen—The reasons underlying low patient recruitment may be low
financial incentives and low motivation levels from participating sites. This may partially be
due to anonymous relations with sponsor and CRO. Furthermore, if inclusion/ exclusion
criteria are very strict, and the screen failure rate is high, a trial may become unattractive
financially for a site. Payment for screen logs may be considered and will sometimes be
used to check commitment to the study. However, it is also costly and does not add to
inclusion.
The potential advantages of an ARO include, but are not limited to, more local/regional
commitment. Often, an academic group is not able to keep all patients in their own hospital
because their capacity (both in-hospital and in their out-patient clinic) is limited, but it can
work together with local/regional non-academic sites and make agreements about referring
patients for specific trials. Agreements can be made about authorships and participation in
writing articles. In most AROs, the primary incentive is scientific and not financial. Such
cooperation may work very well with investigator initiated studies, which have a lower
budget, but it can also work in industry trials. In general, lines are shorter and less expensive
in AROs, and small-to-medium size studies can be managed (up to 1,000 patients more or
less). Clearly, the ARO needs to have the same quality standards as commercial, non-
academic CROs. Commercial sponsors (industry) may sometimes use an ARO (or a group
of them) instead of a commercial CRO.
National Heart Lung and Blood Institute
Monica Shah—The primary goals of the National Heart Lung and Blood Institute
(NHLBI) for site selection are to conduct high-quality, streamlined and cost-efficient trials
by selecting fewer, but better performing sites. However, there is no official policy for site
selection. There is a peculiar paradox that exists in trial execution—we perform clinical
trials to generate evidence to improve patient outcomes; however, we conduct clinical trials
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like anecdotal medicine: (1) we do what we think works; (2) we rely on experience and
judgment; and (3) limited data to support best practices.
The NHLBI site selection process involves two phases: peer-review and after peer-review.
Peer reviewers evaluate site performance and selection based on experience and judgment in
regard to feasibility. Specific requests for applications or requests for proposals may have
more detailed criteria for site selection. For example, the Heart Failure Clinical Research
Network Regional Clinical Centers details the following performance requirements: number
of patients recruited, timeliness of enrollment, end point completion, patient retention, data
quality and timeliness. Peer reviewers are also required to evaluate information about
potential study populations in terms of women and minorities (National Institutes of Health
Revitalization Act 1993). Recruitment targets for all clinical trials are 50 % women and 30
% total minority component. If the proportion of women or minorities is lower, then the
reason(s) for the discrepancy must be identified.
After the peer-review process is complete, NHLBI staff assists in reviewing and monitoring
site selection. With investigators, NHLBI staff develops trial-specific criteria to optimize
site selection and ensure women and minority targets are addressed. Site selection criteria
include: scientific integrity of sites; experience with large, randomized trials; prior
performance, recruitment, data quality; case mix and clinical practice; availability of
essential resources including study coordinators, research pharmacy; availability of
specialized resources including imaging; experience with unique trial procedures such as
waiver of informed consent, surgical technique; diversity of patient population and;
geographic representation. International sites are selected based on heterogeneity of patient
population, prevalence of disease, background therapies utilized and healthcare systems in
place. The National Institutes of Health has specific policies as well for international
recruitment: (1) International recruitment can be counted toward target enrollment; (2)
Information about women and minority recruitment must be reported separately for US and
international sites; and (3) International reports should include the same categories as US
sites.
Thus, the NHLBI uses general guidelines, but possesses no official policy for site selection.
It largely relies on experience and judgment of peer reviewers, investigators and staff.
However, it includes an official policy for women and minority recruitment. Selection and
performance metrics would certainly enhance conduct of trials. A future possibility to help
bolster trial participation and enrollment efficiency is the creation of HF-specific NHBLI-
sponsored standing networks. This system may assist in building upon prior success in this
area to guide future HHF clinical trials.
Industry
Frank Misselwitz: Bayer—In the past, trials were prohibitively expensive without
enrolling enough quality patients. In order to avoid a high number of sites with only 1–2
patients, we must reduce the geographic footprint, not overextend our established resources,
and focus on including sites with a proven track record (high enrolling, high-quality sites).
We must anticipate downstream problems in the trial by performing dry runs, pre-screening,
pre-trial registries, etc.
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There needs to be a new paradigm of how industry, academia and CROs work together.
Conventional performance (and payment) metrics of CROs typically favor opening multiple
sites with frequent visits even in the absence of patients. It is much better to invest into
operational capabilities of sites (study nurses for example)— which perhaps is the most
important single lever to improve our trials. AROs typically have the full scientific
background and access to high volume sites; however, clinical operations, quality assurance
and rigid payment schedules based on key performance indicators are not (yet) engrained in
(most) AROs.
Industry fully supports the initiatives of academia to establish AROs or Academic Research
Teams. Together, we must seek to determine the best agents for the best sub-populations of
patients (patient segmentation). We should search for and validate surrogate markers and
different imaging modalities (cardiac magnetic resonance imaging, echo, etc.,) that can be
utilized in clinical trials. Metrics that can be used to help select high-quality sites include
past performance, benchmark trials, scientific interest, operational capabilities, general
interest in measuring quality of patient care and improving healthcare delivery (hospitalist,
epidemiology, quality systems in place), high number of eligible patients (referral site),
functioning systems to follow-up patients after discharge/intervention long-term, and known
and operationalized patient flows with clear responsibilities and adequate staffing.
A pre-trial registry may be an effective strategy to help overcome these stated problems. It
could assist in determining patient volume and patient flow. The instrument could stratify/
subsegment patients into subgroups. It could determine availability, training and willingness
of personnel to operate clinical trials. Finally, it could determine the ability to perform
required diagnostic procedures in due time and the ability to produce high-quality,
reproducible procedures/intervention results.
Eva Muhlhofer: Bayer—In most studies, 50 % of the countries involved contribute 90 %
of the patients, as many sites enroll zero to two patients. Furthermore, with less experience,
low recruiting sites have many protocol violations which have a major impact on costs,
study duration and affect study outcome.
New tools to improve site selection and study management are needed. There are initiatives
to use electronic health record systems and to link them to clinical trial systems, but all are
at an early stage, and there is no harmonization of these systems. Another option would be
to use a clinical registry, either an ongoing prospective registry or a trial-specific one. Many
topics regarding this must be addressed. Should it be trial-specific? What is the ideal
duration of the registry? Should it include HHF and/or chronic HF patients? What
population size could be representative for global studies? Should it include hospital and/or
outpatient data? Other challenges including time delay, funding and logistics need
discussion. Depending on the overall frame of the registry, it could support drug
development plans, study protocol development, site selection (feasibility checks), patient
selection (capture of patient profiles and patients’ flow data) and safety assessments (current
pre-intervention data), and, in the end, deliver real-life data for reimbursement discussions.
A registry has the opportunity be a tool to support global medical research, improve
healthcare and enhance patient safety.
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The HHF target population is very difficult to define especially if many countries are
participating (different patient care/therapy, length of ICU/hospital stay, early or late
mobilization, etc.). If you harmonize too much, you limit both your population and your
recruitment and fail to reflect real life. If you are too broad, you may miss the population
who benefits. It is not an easy to balance.
Andrew Zalewski: Novartis—Disappointing results of almost all trials in HHF stem
from many factors. The operational issues are compounded by fragmented patient care that
does not allow for a simple identification of investigators within hospital practices. The
pathways of in-hospital care may differ not just in the very acute stage (e.g. presentation to
the ED, acute care facilities) but also during the subsequent hospital stay (e.g. care provided
by internists, cardiologists or commonly other specialties). Other challenges arise from the
often forgotten fact that symptoms of HHF are precipitated by non-cardiac disease.
Analogous to trial planning for acute MI, trial planning in HHF needs to involve both ED
physicians and physicians who will follow the patients during the hospital stay. For
treatments applied beyond the first few hours of presentation and designed to be continued
for weeks or months, it is important to broaden patient pool in clinical trials beyond that
available in cardiology practices (which may skew patient population to lower risk patients).
Other issues that plagued some trials conducted in HHF relate to excessive protocol
complexity. Multiple assessments (biomarkers, imaging) may phenotypically better define
patient population but often reduce enrollment into the trials (“hassle factor”) or shift patient
randomization toward later time point when the benefit of therapy will be more difficult to
ascertain. The sponsors and the academic leadership of the trial should discipline themselves
to simplify inclusion and exclusion criteria, avoid complex assessments, particularly if the
intervention for HHF is to be delivered very early after presentation. Overloading the trials
with sub-studies, although intellectually always attractive, minimizes the chance of success
around the primary hypothesis. In addition, careful pre-trial feasibility is required to assure
that biomarker criteria are readily available in global trial settings.
Fabio Baschiera: Novartis—The validity of a clinical research lays in its application to
the general population. In order to enroll a homogeneous population in HHF clinical trials, it
is necessary to select sites responding to defined characteristics. What are the key ones? We
can recognize 3 main features: (1) the site should be in a hospital operating as an integrated
healthcare provider, with tight interconnections among departments (e.g. ED); (2) electronic
records accessible from all departments with historical data allowing real time admissions
scrutiny as well as reliable estimates of recruitment capabilities; and (3) HF specialists
available for an early diagnosis. Regulatory agencies and sponsors need to recognize the
growing challenges of clinical trials from patient to complex protocol procedures. Such
recognition may contribute to the demand of cost-containment with effects that translate to
reduced drug development costs and a reduced final on-the-shelf price of new drugs.
North American registries
Gregg C. Fonarow—Heart failure registries have been highly successful in enrolling
HHF patients at academic and community based hospitals in the US and elsewhere, even
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when requiring informed consent and post-discharge data collection [26]. In the OPTIMIZE-
HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart
Failure) registry, 48,612 patients were able to be enrolled in less than 24 months from 259
centers [27]. Among 91 sites selected to obtain patient informed consent and capture 60–90
day post-discharge follow-up, 5791 unique HHF patients were enrolled. The majority of
patients screened for enrollment in the registry are able to be successfully enrolled. Heart
failure registries have also been organized to be inclusive of heart failure specialists, general
cardiologists, ED physicians, hospital medicine physicians, primary care physicians, nurses,
allied healthcare personnel and hospital administration [26]. In contrast to the broad
enrollment criteria utilized by registries, most acute HF clinical trials have applied extensive
inclusion and exclusion criteria, resulting in a highly select patient population. Beyond
posing challenges to the identification and recruitment of trial subjects, the external validity
and generalizability of resulting findings generated from highly select clinical trial patient
populations may be significantly limited. There are many lessons from HHF registries that
can be utilized to improve trial design, site selection, evaluation of site performance and
study conduct. Large scale randomized trials for ACS have been successful in part due to
applying lessons learned from ACS registries such as the National Registry of Myocardial
Infarction (NRMI) and aggregating dataset from multiple randomized trials.
North American trialists
Kirkwood F. Adams, Jr. MD—Study process management is a critical element to
excellent study execution. Many sites are plagued by inadequate attention to process
management of the study. Variation in recruitment process is considered acceptable,
ignoring the fact that successful systems share many fundamental methods of work.
Registries can promote common practice of key recruitment strategies, lead to refinement of
strategies and directly assess site performance. If properly designed, conducted and funded,
a Patient- and Site-Based Registry can be used to improve enrollment and quality of HHF
trials. This registry can help assess site process for a trial, ensure that enrollment shows
integrated function of research team at the site and provides funding mechanism to support
trials and offers academic opportunity. Registry enrollment may help guide site selection.
Design features of this registry rely on the premise that both patient and site data are
collected, patients are formally consented for involvement and a detailed log of screening
process is maintained.
John R. Teerlink—Trial execution has appeared to be more successful in the setting of
ACS for several reasons. A clearly defined pathophysiological target is present (“the clot”).
There is a widely held perception among healthcare providers, patients and the community
at-large of a life-threatening disease, and, accordingly, early and continuous involvement of
treating cardiologists is beneficial and is supported by national performance measures. In
contrast, HHF presents unique problems to study conduct and design. A complex
pathophysiological target exists. There is an overwhelming lack of perception that HHF is a
life-threatening condition and multiple care-providers are involved with the management of
these patients. There have been no substantial data supporting early intervention and no
performance measures reaffirming this concept. Due to these underlying differences, an
entirely different approach should be mandated in HHF. We must broaden site selection by
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including increased enrollment from non-academic US community sites with support for
continued site development. Different funding mechanisms should be utilized to allow for
overhead to create and maintain infrastructure for early screening and capture of patients.
Broader inclusion of non-cardiologists (hospitalists, ED physicians) as site PIs and
investigational teams would assist with recruiting. Simplifying Clinical Report Forms
(CRFs) and increased funding (with careful definition) for screening “failures” may also
increase enrollment at the ground-level. Realistic expectations by sponsor (cost and
recruitment/timelines) should be established. Clear academic changes must occur to assist
with the trial process. We must work with academic centers to provide protected time/credit
for enrolling patients in trials. Finally, a re-evaluation of the social contract between the
medical research centers, healthcare payers, pharmaceutical and device sponsors, and
governmental agencies is overdue. All of us benefit from the developments of medical
research, especially in diseases with such high morbidity and mortality like HF.
Malcolm Arnold—Many efforts have been expended but, for many reasons, clinical sites
often enroll only a few patients at a high setup and monitoring cost. The efficiency of HHF
trials may benefit from attention to the detailed process of patient flow. Does the ED team
directly contact the HHF team? How soon does the HHF research team get to the patient?
What is the knowledge and training of housestaff and trainees? Have residents been trained
to present and obtain informed consent for a specific trial? Has the chart been reviewed to
measure gaps in the timeline when patients are “just waiting”? Selecting sites for clinical
trials in HHF will require extensive evidence of the enrollment patterns among sites that
reflect organization/patterns of practice and feasibility. If we focus on high enrollment
strategies in previously successful sites, we may skew the management profile of the
patients that is less generalizable. The selection of new sites may rely on prior experience
with other cardiovascular clinical trials, documented number of HHF patients per year
(along with baseline characteristic snapshot), reviewing existing PIs and staff, available
protected time, letters of support, level of interest and timely response to inquiries. Due to
the narrow window of enrollment, similar to ACS trials, basic and simple metrics should
help guide patient recruitment (e.g. time from arrival in ED to first IV treatment, door to
consent time, door to first study treatment time and completeness of records) (Table 3). An
administrator must assist in removing apparent barriers, change ED protocols as needed,
promote involvement and ownership, make clinical pathways and logistical flow sheet
available for use.
European trialists
John G. Cleland—Investigators need support, encouragement and nurture from all types
of regulatory bodies. Regulations currently focus too much on industry and do not recognize
the huge extra burden this places on investigators. Research is becoming too complex and
too bureaucratic. This discourages potential investigators from participating in trials (Fig. 3).
Protocols and recruitment strategies should be designed so that centers can recruit >30–50
patients per year. Sites have little interest in recruiting 5–10 patients into a study since this
will seldom cover the research costs. The current strategies are not economically viable as,
without subsidized labor (e.g. by “stealing” staff from services or other projects), studies
will result in a net loss to the department. The current reimbursement pattern for CROs
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favors increasing the complexity and workload of clinical trials. Of particular concern are
the poorly remunerated costs of screening. This can be by far the largest cost to the center in
a clinical trial but is often poorly reimbursed, if at all.
There are several possible solutions to this problem. One solution would be to conduct all
clinical trials in Denmark (population ~5 million). Trialists in Denmark are able to recruit
7,000 patients with MI in 2–3 years with 35 hospitals in a 150-mile radius and obtain a clear
mortality result [28]. If we are not able to move all trials to Denmark, we can at least start
with the Danish system. This system of clinical trial execution relies on relatively few, well-
resourced centers with dedicated full-time staff that can enroll consecutive patients. These
centers could also act as ‘National Health Laboratories’ recording the nature and volume of
disease in particular common disease areas. This would ensure their value and continued
existence if a hiatus developed in the trials program and prevent the “stop-start” culture
inherent in existing strategies.
Stefan D. Anker—Site selection is too often based on historic data that is not relevant
since data are outdated, often applied for a different indication and acquired under a
different staff system. Site selection is also based on no data at all and only based on private
relationships and important names. Also, the selection process is underfunded, and forms are
either too complicated (and hence not filled in properly) or filled in by junior staff and/or
simply guesses rather than data driven. Company staff managing trials are sometimes
underappreciating the importance of site selection (e.g. it often happens that when a country
PI is selected, already all sites have been chosen). The free sharing of information regarding
high-quality sites is typically not done. Studies often spread themselves too thin hoping they
will include a few good sites.
Furthermore, the economics of the current clinical trial paradigm does not promote high
enrollment. Recruitment requires at least one full-time person, which costs approximately
60,000 dollars per year. If the study pays 3,000 dollars per patient, then the site must enroll
>15 to make the process sustainable. However, site contracts often only aim for 6 or 10
patients; hence, trial work cannot be economically viable. Ultimately, one good research
fellow given time and support makes all the difference. There may also be problematic
protocols that could use revision. Often, current trial protocols receive input from too many
experts by committee. There is a need for smaller executive committees to design the trial,
which is subsequently approved by a larger body. Exclusion criteria should be stringently
reviewed; patients should be in the trial unless there is a good reason not to be included. The
companies need to develop long-term relationships with investigators, instead of shorter
term need-based interactions. Larger academic centers should be able to deliver >30 or >50
patients, not 5 or 10.
Japanese trialists
Naoki Sato—Regarding the quality of the study, the lack of infrastructure of the
participating centers is one of critical issues, and it might be related to characteristics and the
number of enrolled patients. Based on data from the ATTEND (Acute Decompensated Heart
Failure Syndromes) registry, an ongoing HHF registry in Japan [29], the patient
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characteristics were quite different between daytime- and nighttime-admitted patients, that
is, higher blood pressure and heart rate were observed in patients admitted at nighttime who
were also more likely to have orthopnea, lower pulse oximetry saturation and less peripheral
edema [30]. In Japan, the number of daytime-admitted patients was larger than that of
nighttime-admitted patients, but it would be different in each region or site. Thus, the
characteristics and number of enrolled patients would be influenced by the infrastructure of
the participating center and cause bias in the study.
There is another important issue related to site selection: the regional transportation system.
The transportation time is clearly related to outcome of HHF patients, which was
demonstrated with data from the Tokyo CCU network [31]. In HHF patients, the longer
transportation time, the poorer outcome. Therefore, it might be necessary to evaluate also
the transporting system in the area where the participating sites exist. If regional differences
in transporting system exist, it would be one of major biases in the results of the study.
Incentives
Javed Butler—As a moderator, I was impressed with the robust discussion around the
issue of incentives to participate in clinical trials in academic medical centers. Currently, it
is deemed unethical by most institutional review boards to provide any incentives to boost
enrollment in clinical trials. These include both incentives to patients and to the investigators
and coordinators. The fear about patient incentives is that it may cloud patients’ judgment
and they may agree to take risks that they may otherwise not consent to. The concern for
investigators and coordinators are that incentives may alter unfavorably the process of
complete disclosure of risks to patients and strict adherence to the inclusion and exclusion
criteria for the clinical trial. Industry and academic legal counsels are concerned regarding
incentives of any sort for both ethical reasons but also the potential for negative
consequences from government, regulators and funding agencies. These concerns have
resulted in a situation where almost all incentives are prohibited for anyone involved in
clinical trials. Even small incentives, for example, providing a medical textbook to trainees
to encourage screening patients, are deemed unacceptable. Though the concerns related to
incentives are theoretically true, such deliberate or random unwanted consequences are not
inevitable. The current processes already in place for evaluation, initiation and conduct of
trials include contract negotiations, billing compliance, institutional review board approval,
and in many institutions, a clinical trial oversight and monitoring committee. These
processes have significant labor and financial startup costs, and the process can last several
months. However, built within these steps are mechanisms that can mitigate the chances for
abuse of incentives.
It was generally felt that investigators did not get adequate protected time or salary support
needed for the successful conduct of clinical trials. The investigators then depend on a
variety of staff and colleagues, who in turn uniformly have almost no incentive to make the
trial a success. Currently, the coordinator’s salary cannot be tied to the rate of enrollment.
There are a series of activities that the coordinators perform that can be enhanced, provided
these were linked to incentives build into their performance metric, for example, extra effort
to screen patients from a wider outpatient and inpatient settings than only the cardiology
Gheorghiade et al. Page 17






















floors, be enthusiastically available to other physicians and patients’ families for all
questions related to trials, develop mechanisms with information technology, hospital
medicine, emergency department to maximize enrollment possibilities, develop good
communication with various clinics and hospital floor staff, utilize time efficiently, enroll
patients despite knowing the fact that per protocol some of the procedure may have to be
performed off usual duty hours based on when the patient presented to the hospital, etc.
These and multiple other steps are dependent on motivation of an individual. If the
coordinator’s salary is unaffected regardless of the performance on these steps and they
cannot be incentivized in any form, then the only real incentive, besides the motivation to do
the “right” thing, is that non-productivity may lead to cessation of the research program.
However, this negative, as opposed to positive, incentive likely drives lowest possible bar as
performance target.
Finally, most of the site investigators will not be authors on manuscripts, do not drive
monetary benefits from participation, do not have protected time, and continue to be
stretched in multiple directions in the rapidly changing healthcare environment. However,
the investigator assumes regulatory and legal risks. During the discussion, it was generally
felt that in the current economic and healthcare reform environment, the institutional
academic leadership does not value participation in multi-center clinical trials by the faculty,
unless it is an investigator initiated trial that brings substantial funding to the institution.
Although the group recognized the potential problems with incentives, the general
consensus was that completely prohibiting all incentives to all individuals, especially the
coordinators, is a significant impediment to success. It was recommended that beyond the
investigators, the dialog around incentives in clinical trials should also include other critical
stakeholders including the legal counsels from government, academia, and industry,
ethicists, and business leaders. This dialog will provide a comprehensive view on the
promises and pitfalls of incentives. This will inform the potential considerations for
changing the current paradigm from no incentives to acceptable incentives while strictly
maintaining ethically sound boundaries in conjunction with patient safety and autonomy.
Impediments to patient recruitment into clinical trials of HHF
Hani N. Sabbah—In the United States as well as in Western Europe, enrollment of
patients into clinical trials of HHF and, for that matter, all other HF trials has markedly
dropped in the last decade. While most clinical trial sponsors, clinical trialists, AROs and
CROs are aware of this drop, none have undertaken a systematic review of the underlying
impediments to patient recruitment into clinical trials for HHF. The following is a list of real
or perceived impediments to the recruitment of patients into such clinical trials.
The adverse impact of changing healthcare policies on physician compensation: In
recent years, healthcare organizations and hospitals have linked “compensation” to clinical
care performance. In the United States, this has taken the form of “Relative Value Units” or
RVUs. Physicians are required to generate a minimum number of RVUs per year to
maintain their annual compensation level. RVUs accumulated above this minimum can
often trigger additional compensation in the form of “bonuses”. These RVUs, however, are
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earned for work performed in the course of patient care and not for work performed as an
investigator in a clinical trial. For this reason, many academic physicians who are named
investigators on clinical trials spend most, if not all their time, generating so-called clinical
RVUs and devote less of their time on clinical trials. This healthcare policy shift has created
a culture of “disincentiveness” on the part of physicians to devote precious time to research
endeavors.
The adverse impact of changing healthcare policies on research coordinators: Changes
in physician compensation as a result of the changing healthcare policies have also had a
negative impact of the effectiveness of the traditional clinical trial team of “physician leader
and support coordinators/nurses”. The lack of availability of the physician leader on a
regular basis to help recruit patients into clinical trials has left this entire responsibility to
site coordinators. While these individuals are often hard working and efficient, they cannot
replace the role of the physician in “consenting patients” for a clinical trial. Patients,
regardless of their level of illness, want assurances from their physicians that their
participation in a clinical trial is in their best interest. Lack of physician interaction in
recruitment process often leads to refusal of informed consent by the patient. The resulting
“low enrollment” into a clinical trial at a trial site can lead to a “blame game” between
principal investigator and coordinators that promotes further ineffectiveness and further
deterioration of patient recruitment.
The fading support of fellow faculty physicians: An issue in many academic institutions is
the participation of other faculty physicians within the institution that are not officially part
of a given clinical trial, in helping in the patient recruitment process. There is an ever
increasing discontent among physicians and nurses who are not active parts of a clinical
trials to feel that their contributions to patient recruitment brings them nothing in return for
their efforts. This situation has given rise to the frequent rhetorical response of “what is in it
for me” when asked to refer patients to the trial. Principal investigators on clinical trials are
perceived as having the “privilege” of travel, authorship of academic publications and
presentation at scientific conferences when the referring physician is often denied such
participation. The absence of reward of any kind aside from the goodwill of fellow physician
contributes to a climate of “disincentiveness”.
The conflict of interest barriers: In recent years, universities, major medical centers and
hospitals have introduced policies to limit so-called “conflicts of interest” between members
of their faculty and the medical industry in general. The barriers erected by both medical
institutions to limit “perceived conflicts” have taken their toll on the conduct of clinical
trials and on the recruitment of patients into such trials. In many instances, physicians
serving as site principal investigators are prohibited from participating in any other activities
organized by the sponsor of the trial on which they serve as a principal investigator. Other
faculty members from a clinical trial site who are not principal investigators on the trial are
often also prevented from participating in activities of the trial such as Data and Safety
Monitoring Boards and Steering Committees for fears of perceived conflicts. These issues
have created an environment of distrust and “disincentiveness” on the part of key opinion
leaders from encouraging participation in clinical trials for fear of being found in conflict
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with institutional policies. These barriers, while well intended and perhaps necessary, have
removed the desire on the part of young clinicians and future medical opinion leaders from
seeking participating in the “clinical trial” forum and from contributing effectively to this
essential activity.
The institution view of the clinical trial enterprise: There were times when academic
medical centers looked forward to participating in clinical trials. Their reward was
articulated in the form of contribution to the advancement of science and patient care and the
value of notoriety among peers. In fact, many institutions worked at creating the necessary
environment and infrastructure to ensure the success of clinical trial activities. In recent
years, this positive attitude has been tempered considerably. Many institutions view the
participation in clinical trials only in terms of its “revenue potential”. Institutional indirect
costs and start-up costs have increased dramatically to maximize such revenues. No test
conducted as part of a clinical trial is left unaccounted for in the final budget. This
transformation of “no support for unfunded clinical research” has also helped nourish a state
of “disincentiveness” among the medical and scientific faculty.
The paradoxical influence of high standards of care: Last but by no means least is the
problem of identifying the proper patients that can be recruited into a clinical trial of HHF.
In the United States, regulatory agencies mandate that patients entered into clinical trials
must be optimally medicated as per practice guidelines. Patients are often excluded because
of inadequate therapy at time of screening and often require additional months of therapy
before becoming eligible. Over the years, the exclusion criteria for entry into clinical trials
have also expanded to ensure that only those who are likely to benefit from the test article
are included. This focus on sub-populations, while appropriate to better select effective
therapies for each subset of patients with HHF, makes it more difficult to recruit patients
that meet all inclusion and exclusion criteria. Patients with HF also live longer as a result of
marked advancement in therapy. As a result, the population is aging, and the frequency of
comorbid conditions is on the rise, making it yet more difficult to recruit patients that fulfill
the needs of the trial.
Concluding remarks
Mihai Gheorghiade—In summary, the key components necessary to deliver successful
HHF trials include knowing the drug, matching the drug with the right patient population,
and utilizing the appropriate investigators and sites. Current standards for trial conduct have
established low benchmarks for patient recruitment. The experiences in recent international
trials of HHF have routinely shown the vast majority of site centers either do not enroll any
patients or deliver very low total enrollment counts.
This meeting will serve as a guide to help identify the “right” sites for HHF trials in the
setting of increasing globalization. This document reflects the range of viewpoints present at
a roundtable discussion hosted by the FDA. Members from academia, the NIH, industry,
CROs, AROs and trialists have offered their unique perspectives and potential solutions to
this critical issue. Most agree that there is an unmet need to develop strategies to identify the
right study sites that have acceptable patient quantity and quality. Common themes that were
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identified include, but are not limited to, establishing a pre-trial registry, developing site
performance metrics, identifying a local regionally involved leader and bolstering
recruitment incentives.
Although Albert Einstein wisely stated that “we cannot solve problems by using the same
kind of thinking we used when we created them” and that “if I had an hour to save the
world, I would spend 59 min defining the problem and 1 min finding solutions”, we have
now come to the minute in which we need to find solutions for HHF trials and for HHF
patients.
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Mechanisms for the globalization of clinical trials in heart failure [32]. (US United States,
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Interaction between heart failure site selection, geographical differences and trial
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Complexity of the clinical trial enterprise
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Table 1
Differences between oncology and cardiology clinical trials
HF research AMI research Oncology research










Well-established and effective Less developed, less
beneficial
Subgroup selection Absent Fair (ST elevation, troponins) High (Genetic)
Surrogate endpoints Still uncertain Present (i.e. troponins) Present
Pre-trial clinical research
models
Uncertain Established Present [33]
Trial endpoints Independent from treatment
(mortality)




AMI acute myocardial infarction; HF heart failure
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Table 2
Heart failure study metrics
HF Study Metrics Emergency department metrics
Prior performance Dedicated ED research staff
Monthly screening Annual ED census
ED door to screening time Prior ED HF study participation
ED door to enrollment time Point of care lab
Daily hours of research team
availability
ED physician site co-principal
investigator
Days per week of research team
availability
ED HF admissions by month for
prior year
Research call system for off hours
24/7 enrollment
ED emergency department; HF heart failure
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Table 3
Impact of patient flow on heart failure trial efficiency: metrics for improvement
Phase of hospital care Metric
ED evaluation and treatment for suspected worsening HF (CXR, O2, diuretics,
nitrates, etc.)
What treatments were provided to the patient?
Evaluation for other potential conditions (pneumonia, COPD, PE, etc.) What conditions from the differential diagnosis were
excluded?
Consult with, or transfer care to, other physicians How long did this take?
Admission to hospital ward Utilization of hospital resources
Complications during hospital stay Renal dysfunction? Hypotension? Death?
Discharge and plan for outpatient care Post-discharge readmission rate survival
COPD chronic obstructive pulmonary disease, CXR chest X-ray, ED emergency department, PE pulmonary embolism, HF heart failure
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Table 4
Selecting Investigators and Sites for global clinical trials in patients hospitalized for heart failure (HHF):
current state and future direction—Program Agenda
Location:     FDA White Oak Campus, Building 22, Room 2205, Silver Spring, Maryland
Date:     Thursday, January 12, 2012 8:00 AM–2:30 PM
Time Topic Presenter
8:00–8:10 Welcome Norman Stockbridge
8:10–8:30 Trials in HHF to date: an overview Mihai Gheorghiade
8:30–8:50 Geographical Disparities in HHF Trials Marco Metra
Perspectives on the current process of site selection
Moderator: Marco Metra
8:50–9:00 Characteristics of an “ideal site” Gadi Cotter
9:00–9:10 Contract research organization Chris Giordano
9:10–9:20 Academic Research Organization Frank Peacock
9:20–9:30 National Heart Lung and Blood Institute Monica Shah/Alice Mascette
9:30–10:00 Coffee Break
10:00–10:10 Industry Andrew Zalewski
10:10–10:20 North American trialist Kirkwood Adams
10:30–10:40 European trialist Stefan Anker
10:50–11:30 Group discussion
11:30–12:15 Lunch
Opportunities to improve site selection
Moderator: Javed Butler
12:15–12:30 A Proposal: A Pre-Trial Registry/Instrument Mihai Gheorghiade
12:30–12:40 A Contract Research Organization view Chris Giordano
12:40–12:50 An Academic Research Organization view Dirk van Veldhuisen
12:50–13:00 A National Heart Lung and Blood Institute view Monica Shah/Alice Mascette
13:00–13:10 Industry view Frank Misselwitz/Eva Muehlhofer
13:10–13:20 North American trialist view John Teerlink/Malcolm Arnold
13:20–13:30 European trialist view Stefan Anker/Marco Metra
13:30–13:40 FDA view Norman Stockbridge
13:40–13:55 TIMI study group experience Eugene Braunwald
13:55–14:25 Group discussion
14:25–14:30 Concluding remarks M. Gheorghiade and N. Stockbridge
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